Pediatric Dose Optimization for Seizures in Emergency Medical Services

Purpose

The Pediatric Dose Optimization for Seizures in Emergency Medical Services (PediDOSE) study is designed to improve how paramedics treat seizures in children on ambulances. Seizures are one of the most common reasons why people call an ambulance for a child, and paramedics typically administer midazolam to stop the seizure. One-third of children with active seizures on ambulances arrive at emergency departments still seizing. Prior research suggests that seizures on ambulances continue due to under-dosing and delayed delivery of medication. Under-dosing happens when calculation errors occur, and delayed medication delivery occurs due to the time required for dose calculation and placement of an intravenous line to give the medication. Seizures stop quickly when standardized medication doses are given as a muscular injection or a nasal spray. This research has primarily been done in adults, and evidence is needed to determine if this is effective and safe in children. PediDOSE optimizes how paramedics choose the midazolam dose by eliminating calculations and making the dose age-based. This study involves changing the seizure treatment protocols for ambulance services in 20 different cities, in a staggered and randomly-assigned manner. One aim of PediDOSE is to determine if using age to select one of four standardized doses of midazolam and giving it as a muscular injection or nasal spray is more effective than the current calculation-based method, as measured by the number of children arriving at emergency departments still seizing. The investigators believe that a standardized seizure protocol with age-based doses is more effective than current practice. Another aim of PediDOSE is to determine if a standardized seizure protocol with age-based doses is just as safe as current practice, since either ongoing seizures or receiving too much midazolam can interfere with breathing. The investigators believe that a standardized seizure protocol with age-based doses is just as safe as current practice, since the seizures may stop faster and these doses are safely used in children in other healthcare settings. If this study demonstrates that standardized, age-based midazolam dosing is equally safe and more effective in comparison to current practice, the potential impact of this study is a shift in the treatment of pediatric seizures that can be easily implemented in ambulance services across the United States and in other parts of the world.

Condition

  • Seizures

Eligibility

Eligible Ages
Between 6 Months and 13 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Witnessed by the paramedic to be actively seizing, regardless of seizure type or duration; AND - Under the care of a paramedic; AND - Transported by an EMS agency participating in the study

Exclusion Criteria

  • A prior history of a benzodiazepine allergy; OR - Known or presumed pregnancy; OR - Severe growth restriction based on the paramedic's subjective assessment

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
This is a stepped-wedge, cluster-randomized trial. Every 2 months, 1 of the 20 sites will transition, in a staggered manner, from the control (conventional protocol with calculation-based dosing) to the intervention (standardized protocol with age-based dosing), such that all 20 sites will ultimately implement the intervention during the 4-year enrollment period.
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)
Masking Description
Neurologists will assess the primary outcome of seizing on emergency department arrival using a rapid response electroencephalogram (RR-EEG) that is applied to the patient's scalp upon arrival. Site-specific identifiers will not be available to the neurologist when reading the RR-EEG, so they will be masked to whether the patient was treated under the conventional or standardized protocol. Since the participants' parents will likely see how the paramedics select the midazolam dose and may share that with the participant, they will not be masked to the intervention. The paramedics are the care providers, and they will not be masked to the intervention since their medical director must inform them when their seizure treatment protocol switches from the conventional to the standardized protocol. The investigators will not be masked because they will conduct the training of the paramedic trainers at each site between randomization and implementation of the intervention.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Intervention
This arm will be exposed to the study intervention: a standardized seizure protocol.
  • Drug: Standardized seizure protocol
    The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
    Other names:
    • midazolam
Active Comparator
Control
This arm will be exposed to the emergency medical services (EMS) agency's existing seizure protocol; this is the control arm
  • Drug: Conventional seizure protocol
    The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal. for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
    Other names:
    • midazolam

Recruiting Locations

University of Arizona
Tucson, Arizona 85724
Contact:
Joshua B Gaither, MD
520-626-1670
jgaither@aemrc.arizona.edu

Children's Hospital of Los Angeles
Los Angeles, California 90027
Contact:
Todd P Chang, MD, MAcM
323-361-2109
tochang@chla.usc.edu

University of California, Davis
Sacramento, California 95817
Contact:
Daniel Nishijima, MD, MAS
916-734-3884
dnishijima@ucdavis.edu

University of California, San Francisco
San Francisco, California 94143
Contact:
Nicolaus Glomb, MD, MPH
415-476-3345
nicolaus.glomb@ucsf.edu

University of Colorado
Aurora, Colorado 80045
Contact:
Kathleen Adelgais, MD, MPH
303-724-2595
kathleen.adelgais@childrenscolorado.org

Children's National Hospital
Washington, District of Columbia 20010
Contact:
Kathleen Brown, MD
202-476-4177
kbrown@childrensnational.org

Emory University
Atlanta, Georgia 30322
Contact:
Claudia R Morris, MD
404-727-5500
claudia.r.morris@emory.edu

Indiana University
Indianapolis, Indiana 46202
Contact:
Gregory W Faris, MD
317-962-3886
gfaris@iu.edu

University of Michigan
Ann Arbor, Michigan 48105
Contact:
Stacey Noel, MD
734-763-7488
sknoel@med.umich.edu

University at Buffalo
Buffalo, New York 14203
Contact:
Brian Clemency, MD
716-645-9726
bc34@buffalo.edu

Mecklenburg EMS
Charlotte, North Carolina 28226
Contact:
Douglas Studnek, MD
704-355-2000
dswanson@medic911.com

Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
Contact:
Lauren Riney, DO
513-803-2969
lauren.riney@cchmc.org

Nationwide Children's Hospital
Columbus, Ohio 43205
Contact:
Julie Leonard, MD, MPH
614-722-4384
julie.leonard@nationwidechildrens.org

Oregon Health and Sciences University
Portland, Oregon 97239
Contact:
Matthew Hansen, MD, MCR
503-494-7551
hansemat@ohsu.edu

University of Pittsburgh
Pittsburgh, Pennsylvania 15224
Contact:
Sylvia Owusu-Ansah, MD, MPH
412-692-7692
sylvia.owusuansah@chp.edu

University of Texas Southwestern
Dallas, Texas 75235
Contact:
Geoffrey Lowe, MD
214-456-1359
geoffrey.lowe@utsouthwestern.edu

Baylor College of Medicine
Houston, Texas 77030
Contact:
Kathryn M Kothari, MD
832-824-5497
kathryn.kothari@bcm.edu

University of Utah
Salt Lake City, Utah 84108
Contact:
Maija Holsti, MD, MPH
801-587-7450
maija.holsti@hsc.utah.edu

University of Washington
Seattle, Washington 98104
Contact:
Andrew Latimer, MD
206-521-1588
alatim@uw.edu

Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Lorin Browne, DO
414-266-2625
lbrowne@mcw.edu

More Details

NCT ID
NCT05121324
Status
Recruiting
Sponsor
Stanford University

Study Contact

Manish I Shah, MD, MS
650-723-3319
mshah5@stanford.edu